SIOBHAN FORBES: Open Payments
NPI 1104360825 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 29 payments from 13 companies in 2025. Trend: 2023 $412 · 2024 $580 · 2025 $938
Food & beverage: $938
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $426 |
| Madrigal Pharmaceuticals | 2 | $152 |
| Phathom Pharmaceuticals, Inc. | 8 | $80 |
| Janssen Biotech, Inc. | 3 | $58 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Novo Nordisk Inc | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
Products named: SKYRIZI, REZDIFFRA, RINVOQ, TREMFYA, VOQUEZNA, VIBERZI, ZENPEP, XIFAXAN.
Industry payments across MD — which companies pay providers there.
